Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Chinese Patent Office
Teva
Cantor Fitzgerald
Fish and Richardson
McKesson

Generated: March 24, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HYDREA

« Back to Dashboard

Clinical Trials for Hydrea

Trial ID Title Status Sponsor Phase Summary
NCT00127972 2NN & CHARM Long-Term Follow-up Study Completed Boehringer Ingelheim Phase 4 It is desirable to obtain extended follow up data on subjects who participated in the 2NN study and the CHARM study in order to see if the beneficial effect of using nevirapine continues up to 144 weeks of treatment.
NCT00127972 2NN & CHARM Long-Term Follow-up Study Completed International Antiviral Therapy Evaluation Center Phase 4 It is desirable to obtain extended follow up data on subjects who participated in the 2NN study and the CHARM study in order to see if the beneficial effect of using nevirapine continues up to 144 weeks of treatment.
NCT01098084 Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML) Completed Janssen-Cilag Ltd. Phase 2 The aim of this study is to determine the therapeutic efficacy of Decitabine in patients with chronic myelomonocytic leukemia (CMML) diagnosis according to WHO criteria either untreated or previously treated with Hydrea or Etoposide (given orally), non intensive chemotherapy or intensive chemotherapy given more than 3 months before inclusion.
NCT01098084 Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML) Completed Groupe Francophone des Myelodysplasies Phase 2 The aim of this study is to determine the therapeutic efficacy of Decitabine in patients with chronic myelomonocytic leukemia (CMML) diagnosis according to WHO criteria either untreated or previously treated with Hydrea or Etoposide (given orally), non intensive chemotherapy or intensive chemotherapy given more than 3 months before inclusion.
NCT01387763 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Active, not recruiting Thomas Stauffer Larsen Phase 3 The purpose of the study is to compare the efficacy and toxicity including quality of life of two types of low-dose interferon alpha compounds (PegIntron and Pegasys) with hydroxyurea (Hydrea), and to investigate the occurence of neutralizing antibodies against recombinant interferon.
NCT02560935 Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II Recruiting Aminu Kano Teaching Hospital Phase 3 The overall goal of this proposal is to conduct a partial double-blind randomized Phase III clinical trial for primary stroke prevention in children with sickle cell anemia (SCA) in sub-Saharan Africa.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Hydrea

Condition Name

Condition Name for Hydrea
Intervention Trials
Sickle Cell Disease 3
Stroke 2
Sickle Cell Anemia 2
HIV Infections 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Hydrea
Intervention Trials
Anemia, Sickle Cell 4
Stroke 2
Neoplasms 1
Leukemia, Myelomonocytic, Chronic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Hydrea

Trials by Country

Trials by Country for Hydrea
Location Trials
United States 6
France 2
Nigeria 2
Denmark 1
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Hydrea
Location Trials
Tennessee 2
Texas 1
Georgia 1
Florida 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Hydrea

Clinical Trial Phase

Clinical Trial Phase for Hydrea
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Hydrea
Clinical Trial Phase Trials
Completed 2
Not yet recruiting 2
Recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Hydrea

Sponsor Name

Sponsor Name for Hydrea
Sponsor Trials
Aminu Kano Teaching Hospital 3
Vanderbilt University 2
Murtala Muhammed Specialist Hospital 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Hydrea
Sponsor Trials
Other 16
NIH 3
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Teva
Citi
US Army
Fuji
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.